10. A method of reducing occurrence of a cardiovascular event in a hypercholesterolemia male patient, comprising the steps of:
administering daily ethyl icosapentate in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor to the patient,
wherein the patient also suffers from at least two risk factors selected from the group consisting of:
(1) obesity,
(2) hypertension or prehypertension,
(3) diabetes, prediabetes, or abnormal glucose tolerance, and
(4) hypertriglyceridemia and/or low HDL cholesterolemia,
wherein the patient has not previously had a cardiovascular event;
wherein said 3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor is administered to the patient at least one of before, during and after administering the ethyl icosapentate;
wherein the rate of suppression of the cardiovascular event occurrence in the said administered patient group is equal to or more than 55% compared to the control patient group after 2 years or more from the start of said administration, and
wherein the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor is one or more of pravastatin, lovastatin, simvastatin, fluvastatin, atorvastatin, pitavastatin, rosuvastatin, and salts thereof.